a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma
Study Details
Study Description
Brief Summary
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Phase 1/Phase 2 |
Detailed Description
There are limited options for treatment of relapse/refractory Multiple Myeloma. BCMA is expressed on most Multiple Myeloma cells so it is an ideal target for CAR-T. In this study, investigators will evaluate the safety and efficacy of prime CAR- T targeting BCMA in patients with relapsed/refractory Multiple Myeloma. The primary goal is safety and efficiency assessment, including adverse events and disease status after treatment.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: BCMA targeted prime CAR-T cells treat Patients will be be treated with BCMA targeted prime CAR-T cells |
Biological: BCMA targeted prime CAR-T cells
BCMA targeted prime CAR-T cell therapy
|
Outcome Measures
Primary Outcome Measures
- Adverse events that related to treatment [2 years]
Therapy-related adverse events will be recorded and assessed according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0)
- The response rate of BCMA targeted prime CAR-T treatment in patients with relapse/refractory Multiple Myeloma that treatment by BCMA targeted prime CAR-T cells therapy [2 years]
The response rate of BCMA targeted prime CAR-T treatment will be recorded and assessed according to the IMWG
Secondary Outcome Measures
- Rate of BCMA targeted prime CAR-T cells in bone marrow and peripheral blood [2 years]
In vivo (bone marrow and peripheral blood) rate of BCMA targeted prime CAR-T cells were determined by means of flow cytometry
- Quantity of BCMA targeted prime CAR copies in bone marrow and peripheral blood [2 years]
In vivo (bone marrow and peripheral blood) quantity of BCMA targeted prime CAR copies were determined by means of qPCR
- Quantity of clonal plasma cells in bone marrow [1 years]
In vivo (bone marrow) quantity of clonal plasma cells
- Levels of IL-6 in Serum [1years]
In vivo (Serum) quantity of IL-6
- Duration of Response (DOR) of BCMA targeted prime CAR-T treatment in patients with refractory/relapsed multiple myeloma [2 years]
DOR will be assessed from the first assessment of sCR/CR/VGPR/PR to the first assessment of recurrence or progression of the disease or death from any cause (censored)
- Progress-free survival(PFS) of BCMA targeted prime CAR-T treatment in patients with refractory/relapsed multiple myeloma [2 years]
PFS will be assessed from the first prime CAR-T cell infusion to death from any cause or the first assessment of progression (censored)
- Overall survival(OS) of BCMA targeted prime CAR-T treatment in patients with refractory/relapsed multiple myeloma [2 years]
OS will be assessed from the first prime CAR-T cell infusion to death from any cause (censored)
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Signed written informed consent;
-
Diagnose as relapsed /refractory multiple myeloma, and meet one of the following conditions:
-
Failed to standard chemotherapy regimens;
-
Relapse after complete remission, high-risk and / or refractory patients ;
-
Relapse after hematopoietic stem cell transplantation;
-
Evidence for cell membrane BCMA expression
-
All genders, ages: 18 to 75 years#
-
The expect time of survive is above 3 months;
-
KPS>60
-
No serious mental disorders ;
-
Left ventricular ejection fraction ≥50%
-
Sufficient hepatic function defined by ALT/AST≤3 x ULN and bilirubin≤2 x ULN;
-
Sufficient renal function defined by creatinine clearance≤2 x ULN;
-
Sufficient pulmonary function defined by indoor oxygen saturation≥92%; 12. With single or venous blood collection standards, and no other cell collection contraindications;
-
Ability and willingness to adhere to the study visit schedule and all protocol requirements.
Exclusion Criteria:
-
Previous history of other malignancy;
-
Presence of uncontrolled active infection;
-
Evidence of disorder that need the treatment by glucocorticoids;
-
Active or chronic GVHD
-
The patients treatment by inhibitor of T cell
-
Pregnant or breasting-feeding women;
-
Any situation that investigators regard not suitable for attending in this study (e.g. HIV , HCVinfection or intravenous drug addiction) or may affect the data analysis.
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | 920th Hospital of Joint Logistics Support Force | Kunming | Yunnan | China |
Sponsors and Collaborators
- Chongqing Precision Biotech Co., Ltd
Investigators
- Principal Investigator: Sanbin Wang, MD, 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China
- Principal Investigator: Cheng Qian, PhD, Chongqing University Cancer Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- PBC027